Table 1 Baseline characteristics and biomarker findings (MCI participants, n = 38)

Mean age, yr

70.82 ± 5.56

Female, n (%)

29/38 (76.32%)

Education, yr

7.74 ± 3.47

Hypertension (%)

26/38 (68.42%)

Diabetes mellitus (%)

16/38 (48.48%)

Hyperlipidemia (%)

11/38 (37.93%)

APOE4 allele (%)

11/38 (33.33%)

Plasma amyloid β, ng/mL

0.80 ± 0.28

Plasma amyloid_positivity, n (%)

23/38 (60.53%)

Volumetry_frontal_lt, ml³

319.17 ± 1334.94

Volumetry_frontal_rt, ml³

73.85 ± 8.97

Volumetry_temporal_lt, ml³

51.75 ± 5.53

Volumetry_temporal_rt, ml³

48.68 ± 5.58

Volumetry_parietal_lt, ml³

50.07 ± 5.80

Volumetry_parietal_rt, ml³

51.04 ± 6.58

Volumetry_occipital_lt, ml³

20.58 ± 2.93

Volumetry_occipital_rt, ml³

21.44 ± 2.82

Volumetry_amygdala_lt, ml³

1.59 ± 0.27

Volumetry_amygdala_rt, ml³

1.74 ± 0.34

Volumetry_hippocampus_lt, ml³

3.99 ± 0.46

Volumetry_hippocampus_rt, ml³

4.21 ± 0.52

WMH, volume, ml³

6.11 ± 8.42

Lacune, n

0.97 ± 3.00

Microbleed, n

2.31 ± 8.52

K-MMSE total score

24.79 ± 2.76

CDR-Sum of boxes

2.03 ± 0.69

Digit span forward, percentile

72.21 ± 26.11

Boston naming, percentile

26.46 ± 26.67

RCFT copy, percentile

12.04 ± 19.02

SVLT immediate recall, percentile

18.96 ± 17.82

SVLT delayed recall, percentile

14.82 ± 16.78

SVLT recognition, percentile

28.83 ± 24.88

RCFT immediate recall, percentile

15.74 ± 14.92

RCFT delayed recall, percentile

13.08 ± 12.31

RCFT recognition, percentile

24.78 ± 19.22

COWAT phonemic, percentile

30.36 ± 26.99

Stroop Test, percentile

32.94 ± 30.70